NASDAQ · APRE
Healthcare · Biotechnology
$0.81
Up+$0.16 (+25.75%)
Updated Aug 25, 2026, 8:36 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
APRE closed at $0.81 after 21 trading sessions, up 28.89% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 24, 2026 | $0.7042 | $0.85 | $0.6801 | $0.8052 | 2.8M |
| Aug 21, 2026 | $0.6565 | $0.6697 | $0.623 | $0.6403 | 14.85K |
| Aug 20, 2026 | $0.6721 | $0.6926 | $0.6328 | $0.6401 | 38.86K |
| Aug 19, 2026 | $0.6948 | $0.71 | $0.668 | $0.671 | 52.71K |
| Aug 18, 2026 | $0.706 | $0.706 | $0.672 | $0.672 | 10.49K |
| Aug 17, 2026 | $0.679 | $0.719 | $0.67 | $0.69 | 49.46K |
| Aug 14, 2026 | $0.689 | $0.6953 | $0.6573 | $0.6799 | 15.79K |
| Aug 13, 2026 | $0.671 | $0.6816 | $0.6563 | $0.671 | 21.28K |
| Aug 12, 2026 | $0.78 | $0.78 | $0.656 | $0.683 | 28.22K |
| Aug 11, 2026 | $0.671 | $0.6998 | $0.6551 | $0.6601 | 24.18K |
| Aug 10, 2026 | $0.66 | $0.6856 | $0.6389 | $0.6443 | 30.8K |
| Aug 7, 2026 | $0.6351 | $0.67 | $0.6005 | $0.6503 | 38.5K |
| Aug 6, 2026 | $0.613 | $0.6524 | $0.613 | $0.6325 | 22.64K |
| Aug 5, 2026 | $0.619 | $0.63 | $0.60 | $0.621 | 67.45K |
| Aug 4, 2026 | $0.613 | $0.625 | $0.5993 | $0.5993 | 67.9K |
| Aug 3, 2026 | $0.6025 | $0.6575 | $0.5901 | $0.5977 | 152.28K |
| Jul 31, 2026 | $0.635 | $0.6564 | $0.6069 | $0.62 | 50.91K |
| Jul 30, 2026 | $0.609 | $0.635 | $0.609 | $0.635 | 18.3K |
| Jul 29, 2026 | $0.6475 | $0.6487 | $0.5999 | $0.621 | 140.06K |
| Jul 28, 2026 | $0.671 | $0.671 | $0.60 | $0.6137 | 85.44K |
| Jul 27, 2026 | $0.661 | $0.661 | $0.617 | $0.6247 | 18.96K |
The latest Smart Investors Daily articles mentioning APRE.
APRE research
Company profile and research snapshot.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | Wedbush | Outperform | — |
| May 14, 2026 | Wedbush | Outperform | — |
| May 7, 2026 | Oppenheimer | Outperform | — |
| Mar 31, 2026 | Wedbush | Outperform | — |
| Mar 31, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 30, 2026
Next clinical data update from the ongoing Phase 1 dose escalation ACESOT-1051 trial anticipated at a medical meeting in Q4 2026, providing a near-term opportunity to demonstrate continued clinical progress with
Benzinga · Mar 3, 2026
Benzinga · Feb 18, 2026
Aprea Therapeutics shares rise after promising Phase 1 trial results with APR-1051 in cancer treatment.
Benzinga · Feb 18, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning APRE.
